Drug intelligence / Profile preview

Eolo40

Development stage: Preclinical
Lead developer: Eolo Pharma
Modality: Small Molecules
Administration: Oral

Overview

Eolo40 is a small molecule inhibitor of the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway, currently in preclinical development by Eolo Pharma. NF-kB is a key transcription factor involved in inflammatory and immune responses; its dysregulation is linked to neuroinflammation and neuronal death in neurodegenerative diseases. Eolo40 is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, aiming to mitigate neuroinflammatory processes that contribute to disease progression.

Targets

NF-κB

Beyond the preview

Go deeper on Eolo40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eolo40.

Explore the full profile